certify that this correspondence is being deposited with the United ostal Service as first class mail in an envelope addressed to:

AMENDMENT UNDER 37 CFR 1.116 EXPEDITED PROCEDURE -**EXAMINING GROUP 1649** 

**PATENT** 

Attorney Docket No.: 15280W-002100US

Client Ref. No.: E-286-1998/1-US-06

Commissioner for Patents

P.O. Box 1450

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BRENNEMAN et al.

Application No.: 10/049,587

Filed: February 12, 2002

For: ORALLY ACTIVE PEPTIDES THAT PREVENT CELL DAMAGE AND

**DEATH** 

Customer No.: 45115

Confirmation No. 9701

Examiner:

Standley, Steven H.

Technology Center/Art Unit: 1649

AMENDMENT UNDER 37 CFR 1.116. EXPEDITED PROCEDURE EXAMINING

**GROUP 1649** 

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed October 19, 2006 on the abovereferenced application, please enter the following amendments and remarks. Exhibits A-C, a Request for Continued Examination, and a petition for extension of time for two months, from January 19, 2007 to March 19, 2007 are included herein.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 11 of this paper.